scholarly journals POST-MASTECTOMY EXTERNAL BEAM RADIATION FOLLOWED BY HDR SURFACE MOULD BRACHYTHERAPY BOOST VS. EXTERNAL BEAM RADIOTHERAPY ALONE IN HIGH-RISK CASESA RANDOMISED CONTROLLED TRIAL

2018 ◽  
Vol 7 (43) ◽  
pp. 4642-4647
Author(s):  
Arkoprovo Halder ◽  
Partha Sarathi Halder ◽  
Anjan Das ◽  
Soumita Podder ◽  
Sandip Roy Basunia ◽  
...  
Keyword(s):  
High Risk ◽  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
External Beam Radiotherapy ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation ◽  
Brachytherapy Boost ◽  
Radiotherapy Alone ◽  
Randomised Controlled

Stability of white blood cell counts following standard radiation approaches for high-risk adenocarcinoma of the prostate: Implications for combination therapy.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 201-201
Author(s):  
Steven E. Finkelstein ◽  
Francisco A. Myslicki ◽  
Sharon Salenius ◽  
Constantine Mantz ◽  
Neal Shore ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
High Risk ◽  
Complete Blood Count ◽  
External Beam Radiotherapy ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation ◽  
Cell Counts ◽  
Normal Ranges ◽  
Adenocarcinoma Of The Prostate

201 Background: Traditional wisdom has suggested that under some circumstances radiation therapy may be immunosuppressive, thus obviating effective combination approaches with immunotherapy. Our purpose was to test whether standard radiation therapy for high-risk prostate cancer are immune modulating, thereby prohibiting potential combination with cellular based immunotherapies such as sipuleucel-T. Methods: Retrospective analysis of complete blood count with differential (CBC) data was performed on 26 patients with high-risk adenocarcinoma of the prostate undergoing external beam radiation therapy between January 2008 and November 2010. CBC data were collected prior to radiation therapy and at up to 4 time points thereafter, and compared to normal ranges from an outside reference lab (WBC 3,800-10,700/μL; ALC 910-4,280/μL). Results: The median age was 73 (range 62-86), and 16 patients were on concurrent androgen deprivation therapy. Patients received intensity modulated, dose-escalated external beam radiotherapy. Baseline and subsequent median white blood counts (WBC) and absolute lymphocyte counts (ALC) remained within the normal ranges. In the clinically relevant time frame of <3 months following radiation therapy where sipuleucel-T could be considered, the WBC and ALC were 5,350 and 970, respectively. The median WBC and ALC then gradually increased to 5,800 and 1,250, respectively, at 6-12 months post radiation therapy. Conclusions: These data suggest that in the setting of external beam radiation approaches for high-risk adenocarcinoma of the prostate, no significant changes in either WBC or ALC were observed. The hematologic status in these patients remained stable, suggesting that combination radiation / cellular based immunotherapy approaches are feasible. Further analysis is warranted to test the potential of novel immunotherapeutic agents with radiation therapy. [Table: see text]

Trends and oncological outcome of testosterone recovery after androgen deprivation therapy in prostate cancer patients who received external beam radiotherapy.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 345-345
Author(s):  
Akinori Takei ◽  
Shinichi Sakamoto ◽  
Takaaki Tamura ◽  
Ken Wakai ◽  
Maihulan Maimaiti ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Multivariate Analysis ◽  
High Risk ◽  
Androgen Deprivation Therapy ◽  
External Beam Radiotherapy ◽  
Oncological Outcome ◽  
Androgen Deprivation ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation

345 Background: Although androgen deprivation therapy (ADT) combined with external beam radiation therapy (EBRT) is standard treatment for high risk prostate cancer (PC) patients, the shift of testosterone (TST) levels after ADT and the optimal duration of ADT is unclear. TST recovery and outcome were studied in PC patients who received EBRT with ADT. Methods: Eighty-two patients who underwent EBRT with ADT for PC were retrospectively analyzed. Serum TST levels after ADT terminations were studied. Cox proportional hazard models and the Kaplan-Meier method were used for statistical analysis. Results: Median age, baseline TST, nadir TST, and duration of ADT were 73 years, 456 ng/dL, 16 ng/dL, and 26 months, respectively. ADT duration of 33 months (HR 0.13; p=0.0018), nadir TST of 20 ng/dL (HR 0.35; p=0.0112), and TST >50 ng/dL at 6 months after ADT termination (HR 0.21; p=0.0075) were significantly associated with TST recovery to normal levels (200 ng/dL) on multivariate analysis. ADT duration of 33 months (HR 0.31; p=0.0023) and nadir TST of 20 ng/dL (HR 0.38; p=0.0012) were significantly associated with TST recovery to supracastrate level (50 ng/dL) on multivariate analysis. In high risk PC patients, ADT≤ 2 year group showed shorter time to TST recovery to supracastrate levels compare to those of ADT>2 year group (HR 4.21; p=0.0022) without affecting biochemical recurrence (p=0.49) and overall survival (p=0.674). Conclusions: ADT duration of 33 months and nadir TST of 20 ng/dL predicted the TST recovery to suparacastrate levels. Less than 2 year of ADT provided better TST recovery without affecting the oncological outcome in high risk patients.[Table: see text]

Sign in / Sign up

Export Citation Format

Share Document